Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	688.7M	671.0M	504.4M	517.8M	526.5M
Cost of Revenue	132.1M	117.4M	85.0M	96.6M	130.0M
Gross Profit	556.7M	553.7M	419.4M	421.2M	396.4M
Operating Expenses
R&D Expense	40.6M	40.5M	40.3M	46.6M	18.2M
SG&A Expense	—	—	—	—	—
General & Admin Expense	183.6M	172.2M	107.9M	71.9M	57.3M
Selling & Marketing Expense	228.9M	237.2M	201.8M	241.6M	268.7M
Other Expenses	—	—	—	—	—
Total Operating Expenses	475.3M	471.9M	369.7M	378.8M	360.3M
Cost and Expenses	607.4M	589.3M	454.6M	475.4M	490.3M
Operating Income (EBIT)	45.1M	46.4M	41.8M	39.3M	30.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	45.9M	47.3M	41.0M	37.7M	28.8M
Income Tax Expense	3.8M	6.6M	867.3K	1.4M	(3.3M)
Bottom Line
Net Income	44.4M	42.1M	40.2M	36.3M	32.4M
Earnings from Cont. Ops	42.1M	40.7M	40.2M	36.3M	32.1M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	44.4M	42.1M	40.2M	36.3M	32.4M
Per Share
Basic EPS	CN¥0.37	CN¥0.35	CN¥0.34	CN¥0.30	CN¥0.27
Diluted EPS	CN¥0.37	CN¥0.35	CN¥0.34	CN¥0.30	CN¥0.27
Revenue Per Share	CN¥5.74	CN¥5.59	CN¥4.20	CN¥4.31	CN¥4.39
Shares
Basic Shares Outstanding	120.0M	120.0M	120.0M	120.0M	120.0M
Diluted Shares Outstanding	120.0M	120.0M	120.0M	120.0M	120.0M
Profitability Metrics
EBITDA	—	110.4M	94.7M	92.8M	78.2M
D&A	—	64.0M	52.9M	53.5M	48.1M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026